ArticleJACC. Case reports2025
Transseptal Transcatheter Mitral Valve Replacement With a Novel Bioprosthesis in a Patient With Challenging Anatomy.
Article in JACC. Case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundA number of transcatheter-based therapies are emerging as therapeutic options for high-surgical risk patients with moderate-to-severe or severe mitral regurgitation (MR). CASE SUMMARY: This is the first published report of treatment with the fully percutaneous, transfemoral, transseptal Saturn mitral valve replacement device in a 66-year-old woman with 3+ symptomatic MR. Ultimately, the patient had elimination of her MR and symptomatic improvement. DISCUSSION: This transcatheter mitral valve replacement device allows for basal annular stabilization and preservation of the neo-left ventricular outflow tract. Despite the difficult anatomy (small left heart size and limited transseptal height), device implantation was successful with the Saturn delivery system. TAKE-HOME MESSAGE: Saturn transcatheter mitral valve replacement offers a feasible alternative for the treatment of secondary MR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.